(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

AVANT RX

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

AVANT RX

ST13

US500000090572763

Class

35

Filing

90572763

Registration

7545087

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

41

Latest update

10/22/2024

Trademark type

Word

Nice classes

35

Filing date

03/11/2021

Registration date

10/22/2024

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

10/22/2024

Last transaction

10/22/2024

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

2023-12-00

First use in commerce

2023-12-00

Drawing code

4

Owner type

16

Owner location

Charlotte, NC, US

Examiner

LEE,YATSYE ISADORA

Law office

L70

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Afya Group LLC

Representatives

Kathryn A. Gromlovits SHUMAKER, LOOP & KENDRICK, LLP

Technical classification

Nice Classes

Class 35

Vienna Codes

No Vienna codes available.

Goods and services

Class 35

Retail pharmacy services

Publications

History of USPTO decisions and trademark events.

41 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

10/22/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

10/22/2024

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

09/15/2024

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

09/15/2024

SUPC

STATEMENT OF USE PROCESSING COMPLETE

07/25/2024

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

07/25/2024

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

06/13/2024

IUAF

USE AMENDMENT FILED

06/10/2024

EISU

TEAS STATEMENT OF USE RECEIVED

06/10/2024

EX3G

SOU EXTENSION 3 GRANTED

06/04/2024

EXT3

SOU EXTENSION 3 FILED

06/04/2024

EEXT

SOU TEAS EXTENSION RECEIVED

06/04/2024

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

11/08/2023

EX2G

SOU EXTENSION 2 GRANTED

11/06/2023

EXT2

SOU EXTENSION 2 FILED

11/06/2023

EEXT

SOU TEAS EXTENSION RECEIVED

11/06/2023

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

06/01/2023

EX1G

SOU EXTENSION 1 GRANTED

05/30/2023

EXT1

SOU EXTENSION 1 FILED

05/30/2023

EEXT

SOU TEAS EXTENSION RECEIVED

05/30/2023

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

12/06/2022

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

10/11/2022

PUBO

PUBLISHED FOR OPPOSITION

10/11/2022

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

09/21/2022

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

09/08/2022

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

08/09/2022

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

08/09/2022

ALIE

ASSIGNED TO LIE

08/09/2022

ERSI

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

07/20/2022

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

05/05/2022

GNSL

LETTER OF SUSPENSION E-MAILED

05/05/2022

CNSL

SUSPENSION LETTER WRITTEN

05/05/2022

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

04/08/2022

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

04/07/2022

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

04/07/2022

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

10/07/2021

GNRT

NON-FINAL ACTION E-MAILED

10/07/2021

CNRT

NON-FINAL ACTION WRITTEN

10/07/2021

DOCK

ASSIGNED TO EXAMINER

10/07/2021

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

06/10/2021

NWAP

NEW APPLICATION ENTERED

03/15/2021

Continuous trademark protection

Get notified about every new filing that threatens AVANT RX or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.